Literature DB >> 26629424

New strategies in immunotherapy for non-small cell lung cancer.

Daniel R Carrizosa1, Kathryn A Gold1.   

Abstract

Treatment for the most common form of cancer (lung cancer) has historically involved use of cytotoxic chemotherapy. With the advent of mutation analysis, more therapies beyond traditional cytotoxics have been discovered. Most recently, the use of immunotherapy has entered the treatment arsenal of non-small cell lung cancer (NSCLC). This review aims to summarize the current and future use of immunotherapy in the treatment of NSCLC.

Entities:  

Keywords:  Non-small cell lung cancer (NSCLC); immunotherapy; vaccine

Year:  2015        PMID： 26629424      PMCID： PMC4630527          DOI： 10.3978/j.issn.2218-6751.2015.06.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  30 in total

1.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

Authors:  I Melero; W W Shuford; S A Newby; A Aruffo; J A Ledbetter; K E Hellström; R S Mittler; L Chen
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

2.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Authors:  Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò
Journal:  Lancet Oncol       Date:  2012-11-28       Impact factor: 41.316

8.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307
View more
  20 in total

1.  A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC.

Authors:  Petros Christopoulos; Michael Thomas
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

2.  MicroRNAs-491-5p suppresses cell proliferation and invasion by inhibiting IGF2BP1 in non-small cell lung cancer.

Authors:  Fangchao Gong; Ping Ren; Yan Zhang; Jindong Jiang; Hong Zhang
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 3.  Immune checkpoint pathways in non-small cell lung cancer.

Authors:  Young Kwang Chae; Ayush Arya; Wade Iams; Marcello Cruz; Nisha Mohindra; Victoria Villaflor; Francis J Giles
Journal:  Ann Transl Med       Date:  2018-03

4.  MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.

Authors:  Audrey Bouillez; Dennis Adeegbe; Caining Jin; Xiufeng Hu; Ashujit Tagde; Maroof Alam; Hasan Rajabi; Kwok-Kin Wong; Donald Kufe
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

Review 5.  Lung Cancer Biomarkers.

Authors:  Pamela Villalobos; Ignacio I Wistuba
Journal:  Hematol Oncol Clin North Am       Date:  2017-02       Impact factor: 3.722

Review 6.  The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.

Authors:  Jonathan Lu; Robert A Ramirez
Journal:  Ochsner J       Date:  2017

Review 7.  Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.

Authors:  Jianwei Zhu; Yun Yuan; Xiaoyu Wan; Dan Yin; Rui Li; Wenwen Chen; Chen Suo; Huan Song
Journal:  Cochrane Database Syst Rev       Date:  2021-12-06

8.  Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.

Authors:  Charli Dominguez; Kwong-Yok Tsang; Claudia Palena
Journal:  Cell Death Dis       Date:  2016-09-29       Impact factor: 8.469

9.  PD-L1+MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment.

Authors:  Tomoaki Iwata; Yasuteru Kondo; Osamu Kimura; Tatsuki Morosawa; Yasuyuki Fujisaka; Teruyuki Umetsu; Takayuki Kogure; Jun Inoue; Yu Nakagome; Tooru Shimosegawa
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379

Review 10.  Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.

Authors:  Jianwei Zhu; Rui Li; Eva Tiselius; Raheleh Roudi; Olivia Teghararian; Chen Suo; Huan Song
Journal:  Cochrane Database Syst Rev       Date:  2017-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.